OXA-244-Producing Escherichia coli Isolates, a Challenge for Clinical Microbiology Laboratories

Yannick Hoyos-Mallecot (1, 2, 3) , Thierry Naas (1, 4, 2, 3) , Rémy Bonnin (1, 4, 2, 3) , Rafael Patino (4) , Philippe Glaser (4) , Nicolas Fortineau (1, 4, 2, 3) , Laurent Dortet (1, 4, 2, 3)

1 AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre)
2 LabEx LERMIT - Laboratoire d'Excellence en Recherche sur le Médicament et l'Innovation Thérapeutique [Châtenay-Malabry]
3 Centre National de Référence Associé de la Résistance aux Antibiotiques
4 EERA - Ecologie et Evolution de la Résistance aux Antibiotiques / Ecology and Evolution of Antibiotics Resistance

OXA-244 is a single-point-mutant derivative of OXA-48 displaying reduced carbapenemase activity. Here, we report the microbiological features of seven OXA-244-producing Escherichia coli isolates. Only one isolate grew on ChromID Carba Smart medium (bioMérieux), but six of the seven isolates grew on ChromID extended-spectrum-β-lactamase (ESBL) medium (bioMérieux), as they coproduced an ESBL and/or a plasmid-encoded cephalosporinase. The production of a carbapenemase was detected in 57.1%, 71.4%, 71.4%, and 100% of the E. coli isolates using the Carba NP test, the Rapidec Carba NP test (bioMérieux), a matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) hydrolysis assay (Bruker), and the OXA-48 K-SeT assay (Coris BioConcept), respectively. Our results indicate that OXA-244-producing E. coli isolates are difficult to detect, which may lead to their silent spread.

Keywords: OXA-244; OXA-48-like; carbapenemase activity; detection; screening; tests

Domains: Life Sciences [q-bio]

Yannick Hoyos-Mallecot, Thierry Naas, Rémy Bonnin, Rafael Patino, Philippe Glaser, et al.. OXA-244-Producing Escherichia coli Isolates, a Challenge for Clinical Microbiology Laboratories. Antimicrobial Agents and Chemotherapy, 2017, 61 (9), ⟨10.1128/AAC.00818-17⟩. ⟨pasteur-03107799⟩